Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit
HAMILTON, BERMUDA / ACCESS Newswire / January 23, 2026 /Altamira Therapeutics Ltd. ( "Altamira " or the "Company ") (OTCID:CYTOF), a company dedicated to developing and commercializing nucleic acid delivery technology for targets beyond the liver, announced today that it will be presenting at the 5th mRNA-Based Therapeutics Summit Europe, being held January 28-29, 2026, in Berlin. Covadonga Pañeda, Ph.D., Altamira Therapeutics ' Chief Operating Officer, will give a presentation entitled "CycloPhore & SemaPhore enabling next-generation delivery solutions for circular RNA & mRNA therapeutics ".
"There is a strong and growing interest in the use of different RNA modalities for therapeutic purposes " commented Dr. Pañeda. "Both linear mRNA and circular RNA are non-integrating modalities that enable transient protein expression. These modalities primarily differ in the onset, duration, and kinetics of protein expression. Consequently, the choice of modality is highly dependent on the disease to treat. Whereas linear mRNA is excelling where speed, controllability and transient expression are required, circular RNA is typically the modality of choice when enhanced or prolonged expression or reduced dosing are favored. With SemaPhore and CycloPhore we are providing safe, efficient and versatile delivery platforms which maximize the advantages of each of these RNA modalities to treat and prevent acute and chronic indications. "
About SemaPhore™ and CycloPhore™
SemaPhore and CycloPhore are versatile platforms designed to enable safe and effective delivery of mRNA and circular RNA, respectively, into target cells, using systemic or local administration. It is based on a proprietary 21 amino acid peptide that can engage any type of RNA in rapid self-assembly into a polyplex. The polyplex has a size, charge, and other physical features that allow it to escape hepatic clearance and thus reach target tissues other than the liver. SemaPhore and CycloPhore protect the RNA payload from degradation in the circulation and allow for rapid and effective cell entrance. Efficient delivery and positive treatment outcomes have been demonstrated in multiple murine models of disease so far.
About Altamira Therapeutics
Altamira Therapeutics is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The versatile delivery platform is suited for different nucleic acid modalities, including siRNA, mRNA, circRNA, as well as DNA, and made available to pharma or biotech companies through out-licensing. The Company has two proprietary programs based on xPhore and siRNA payloads: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratx.com/
Forward-Looking Statements
This press release may contain statements that constitute "forward-looking statements " within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira 's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may ", "might ", "will ", "should ", "expects ", "plans ", "anticipates ", "believes ", "estimates ", "predicts ", "projects ", "potential ", "outlook " or "continue ", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management 's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include but are not limited to the clinical utility of Altamira 's product candidates, the timing or likelihood of regulatory filings and approvals, Altamira 's intellectual property position and Altamira 's financial position. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors " in Altamira 's Annual Report on Form 20-F for the year ended December 31, 2024, and in Altamira 's other filings with the Securities Exchange Commission ( "SEC "), which are available free of charge on the SEC 's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor Contact:
SOURCE:Altamira Therapeutics Ltd.
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
